Oral Cancer News | Tag Archive

UT MD Anderson article offers one roadmap for defining value in health care, earns national award from leading journal

Friday, February 3, 2012

Source: http://www.newswise.com Author: University of Texas M. D. Anderson Cancer Center A team from The University of Texas MD Anderson Cancer Center is receiving a national award for a research article tackling a question vital to the future of health care with reform regulations looming, competition growing and costs rising. The MD Anderson study took [...]

GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

Saturday, October 15, 2011

0 Comments

Source: http://7thspace.com Author: Chien-Yu Lin et al. Oral cavity cancers (ORC) are the most common cancers, and standard treatment is radical surgery with postoperative radiotherapy. However, locoregional failure remains a major problem, indicating radioresistance an important issue. Our previous work has shown that GP96 contributed to radioresistance in nasopharyngeal and oral cancer cell lines. In [...]

What accounts for racial differences in head/neck cancer?

Monday, September 19, 2011

0 Comments

Source: www.drbicuspid.com Author: DrBicuspid Staff Why are African-Americans more likely than Caucasians not only to be diagnosed with head and neck cancer, but also to die from the disease? While the answer isn’t a simple one, differences in lifestyle, access to care, and tumor genetics may be partly to blame, according to a new study [...]

Sanford researcher to study new oral cancer therapy

Saturday, July 16, 2011

0 Comments

Source: www.mdnews.com Author: public release A new Sanford clinical trial will study the safety and effectiveness of a drug treatment on patients receiving radiation and chemotherapy for head and neck cancer. About three to five percent of all cancers reported in the United States are head and neck cancers. Although the incidence of this type [...]

Polymeric nanoparticles attack head and neck cancer

Saturday, July 16, 2011

0 Comments

Source: www.nanowerk.com Author: staff Head and neck cancer, the sixth most common cancer in the world, has remained one of the more difficult malignancies to treat, and even when treatment is successful, patients suffer severely from the available therapies. Now, researchers at the University of Michigan have developed a tumor-targeted nanoparticle that delivers high doses [...]

Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years

Saturday, March 12, 2011

0 Comments

Source: jco.ascopubs.org Authors: Sagar C. Patel et al. Purpose: To evaluate the incidence of oral cavity squamous cell carcinoma (OCSCC) and oral tongue squamous cell carcinoma (OTSCC) in young white women, age 18 to 44 years. Patients and Methods: We analyzed incidence and survival data from the Surveillance, Epidemiology and End Results (SEER) Program of [...]

In cancer survival, ‘mind matters,’ says expert

Sunday, February 6, 2011

0 Comments

Source: www.medscape.com Author: staff Social support and psychologic/psychiatric interventions can improve survival in cancer but are “overlooked” in the treatment of the disease, argues a psychiatrist in an essay published in the February 2 issue of the Journal of the American Medical Association. “A patient’s personal mental management of the stresses associated with cancer” is [...]

Rash prediction in lung cancer?

Wednesday, January 26, 2011

0 Comments

Source: www.medscape.com Author: Maurie Markman, MD Hello. I am Dr. Maurie Markman from Cancer Treatment Centers of America in Philadelphia. I wanted to briefly discuss with you a very interesting paper[1] that appeared online in The Lancet Oncology on December 20th, 2010, and will be in print soon. The paper was entitled “First-Cycle Rash and [...]

Three-drug combination shows long-lasting survival benefit in head and neck cancer patients

Thursday, January 13, 2011

0 Comments

Source: www.medicalnewstoday.com Author: staff Adding a third drug (docetaxel) to a standard two-drug initial chemotherapy regimen significantly improves the long-term survival of patients with head and neck cancer, reducing the likelihood of dying by 26% over 6 years. The long-term results of the TAX 324 trial published Online First in The Lancet Oncology, confirm that [...]

PMI Labs lowers price of oral cancer brush biopsy test

Saturday, October 23, 2010

0 Comments

Source: www.marketwire.com/ Author: press release PMI Labs is excited to announce that the price of OralAdvance™, the Company’s innovative test designed to detect early stage oral cancer, is lowered by 35% as a result of the completion of the next generation quantitative cytology analysis platform, ClearCyte™. The redesigned and reengineered ClearCyte™ platform allows for faster [...]

Tag Archive | "survival"